Pacira BioSciences (PCRX) Proxy filing summary

Executive summary

• Achieved record revenues of $726.4 million in 2025, a 4% year-over-year increase, with 2.5 million patients treated and significant progress on the 5x30 strategy targeting growth, profitability, pipeline expansion, and partnerships by 2030.

• Expanded commercial reach through partnerships with Johnson & Johnson MedTech and LG Chem, and advanced two Phase 2 clinical programs, with key data milestones expected in 2026.

• Returned $150 million to stockholders via share repurchases, reducing outstanding shares from 47 million to 41 million, and maintained strong cash and investments of $238 million at year-end.

Voting matters and shareholder proposals

• Election of three Class III directors (Christopher Christie, Samit Hirawat, Thomas Wiggans) to serve until 2029; board recommends voting FOR only these nominees and NOT for the three DOMA nominees.

• Ratification of KPMG LLP as independent auditor for 2026; board recommends FOR.

• Advisory vote to approve executive compensation (Say-on-Pay); board recommends FOR.

• Approval of amendments to the 2011 Stock Incentive Plan (adding 2.2 million shares) and 2014 Employee Stock Purchase Plan (adding 800,000 shares); board recommends FOR both.

Board of directors and corporate governance

• Board consists of nine directors post-meeting, with eight independent members and an independent chair.

• Recent board refreshment added five new independent directors since October 2023 and nominated a sixth for election.

• Annual board and committee self-assessments, majority voting in uncontested elections, and robust risk oversight practices.

• Board committees include Audit, People & Compensation, Nominating, Governance & Sustainability, Science & Technology, and Transaction Committees.